Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
about
Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancerIntravesical electromotive drug administration for non-muscle invasive bladder cancerIntravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancerIntravesical gemcitabine for non-muscle invasive bladder cancerIntravesical gemcitabine for non-muscle invasive bladder cancerIntravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working partyIntravesical therapy for non-muscle invasive bladder cancer: a network meta-analysisHigh-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG ShortageReview of current optical diagnostic techniques for non-muscle-invasive bladder cancerHow do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?Active surveillance for nonmuscle invasive bladder cancerComparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladderMolecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment OutcomesHexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladderTreatment options in non-muscle-invasive bladder cancer after BCG failureIntravesical chemotherapy in non-muscle-invasive bladder cancerNon-muscle invasive bladder cancer risk stratificationNew and contemporary markers of prognosis in nonmuscle invasive urothelial cancerCurrent perspectives in bladder cancer managementUrine survivin as a diagnostic biomarker for bladder cancer: a systematic reviewDefining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancerAdvances in imaging technologies in the evaluation of high-grade bladder cancerDeveloping and validating risk prediction models in an individual participant data meta-analysisCell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomenaBacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive DiseaseEmerging endoscopic and photodynamic techniques for bladder cancer detection and surveillanceEmerging critical role of molecular testing in diagnostic genitourinary pathologyComplete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysisEZH2 in Bladder Cancer, a Promising Therapeutic TargetG9a Inhibition Induces Autophagic Cell Death via AMPK/mTOR Pathway in Bladder Transitional Cell CarcinomaA place for precision medicine in bladder cancer: targeting the FGFRs.Dynamic Change in p63 Protein Expression during Implantation of Urothelial Cancer Clusters.Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approachUnique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranosticsCurrent clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).Overall survival advantage with partial nephrectomy: a bias of observational data?Variable selection in subdistribution hazard frailty models with competing risks data.
P2860
Q24186083-D0AE3A2B-972F-4963-93B6-5E0BBC92E58CQ24187574-6D3EE222-94BE-44E1-B995-A6F38D16C67DQ24188295-F55FD9D7-DA1F-44CD-BDEA-A64EE075025CQ24203884-4B56465C-3988-4D4B-8CB0-F9E66A260B00Q24236635-69AD2AE0-4CF0-4E7B-BAF0-BBD1DA28BB82Q24648407-AFA39E07-99BC-430F-A7C0-D7C3337097C0Q26471299-324CE164-5101-4CE5-84FF-D8582EEFC671Q26739003-472FCB38-4FC8-4171-85D8-0C827576E57BQ26739731-CE4767A8-B739-4266-BD71-36FF84D7AD1BQ26744155-F142A635-3081-44AD-8423-E710F5E54560Q26744158-2774A1C5-AC76-4187-864D-FA6D2DE2BFB1Q26744756-19832020-E0BE-4D1A-AC0E-6C57E9C0F105Q26747775-0670A54E-DC35-44AF-8761-6192857D62ACQ26765922-758A0091-2B65-4E00-9505-1A32D5974852Q26775775-5AD669B6-2029-4889-9D15-74316E751E28Q26775977-FAD7B3A7-0C89-44E9-8874-DE83B1B06551Q26775982-0E17516D-F55A-4A07-A77A-C683D4332764Q26775984-4F3DD51E-A595-407B-98A8-E7A7B1FFA89CQ26798006-76ED2289-6EC4-491B-BA58-CDD0E9D43947Q26824914-7099E25C-5BE2-4A72-AB44-E5FBC49EF8CCQ26828933-00017164-700F-4E7E-A7B0-2415C0513A41Q26852084-D075B610-617F-49BB-A121-E1E18527F4FBQ26852856-9F6763A1-0E91-44A4-897D-5A3EDBEE6CAFQ26859694-92CBE027-E120-4A1D-94F1-675C1283A76DQ26860953-D31C4F06-37E8-4A07-B2C8-B66A0C830999Q27011829-7F05E87B-5C0E-40AD-9517-F800948ACBA7Q27014754-A57A6EC8-91E1-491B-A4E4-2A9A400384F9Q27021371-DDD8CDA7-61B7-432F-836B-3BC9953327DCQ27853334-001EC227-F763-407D-8CF4-F065FBB278BCQ28073378-359A2273-0400-4EB1-BCD8-DF5846135535Q28082054-317C9EA9-3643-47DB-89A8-A1712529A6D0Q28548356-DBBA7638-914D-4AC3-8512-EC85A3789476Q30249143-9AE1DF3F-BCE6-411F-8C0D-D2D2CBF8C086Q30403508-AB8130BB-0695-47DD-9BEB-2A60DCE346ACQ30446429-7F8361DB-B6E3-4CB1-9985-E1004DE00549Q30455697-A7BEC64E-F277-497E-AADB-B682E9DF04B3Q30462417-67D6171D-D1DE-402A-81C2-5763763C9133Q30596342-89CB492C-3792-4FCF-A422-E349FE5B64EBQ30626270-D9A1CDC3-B29A-42C3-8BCD-9CEC2EBE0611Q30837437-C40EF086-44F5-4AE5-AEE3-6659FFD2B264
P2860
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Predicting recurrence and prog ...... ients from seven EORTC trials.
@en
Predicting recurrence and prog ...... ients from seven EORTC trials.
@nl
type
label
Predicting recurrence and prog ...... ients from seven EORTC trials.
@en
Predicting recurrence and prog ...... ients from seven EORTC trials.
@nl
prefLabel
Predicting recurrence and prog ...... ients from seven EORTC trials.
@en
Predicting recurrence and prog ...... ients from seven EORTC trials.
@nl
P2093
P1433
P1476
Predicting recurrence and prog ...... ients from seven EORTC trials.
@en
P2093
Adrian P M van der Meijden
Christian Bouffioux
Donald W W Newling
J Alfred Witjes
Karlheinz Kurth
Louis Denis
Richard J Sylvester
Willem Oosterlinck
P304
466-5; discussion 475-7
P356
10.1016/J.EURURO.2005.12.031
P407
P577
2006-01-17T00:00:00Z